Withings Health Solutions Launch BPM Pro 2

Withings Health Solutions Launch BPM Pro 2

Withings Health Solutions has set a new benchmark in heart health monitoring with the launch of BPM Pro 2. This cellular blood pressure monitor is the first of its kind, collecting precise measurements while introducing a new feature that enriches the data with context from patients’ daily lives. 
 
The BPM Pro 2 measures heart rate, and blood pressure and comes with the future capability to take a 1-lead ECG to detect atrial fibrillation (following FDA Clearance). The device is portable, compact, and designed to be user-friendly. 
 
“At-home blood pressure monitoring has become a standard across the industry for managing chronic conditions like hypertension and heart failure but poses a real challenge in making sure the data collected is consistent, reliable, and actionable for care teams. Elevated readings may result from simple factors like improper rest before a measurement or signal more serious issues such as the start of a hypertensive crisis,” said Aline Criton, Chief Clinical and Regulatory Affairs Officer at Withings. “BPM Pro 2 addresses these challenges with advanced features that enhance data reliability and provide contextual patient insights that help care teams differentiate between routine variations and critical health events allowing for more timely and personalized care intervention.”
 
The device supports two cuff sizes (9-17 inches and 16-21 inches), which can be easily interchanged. BPM Pro 2’s vibrant, full-color LCD screen encourages patients to take their measurements more frequently while allowing them to share patient-reported outcomes with their care teams.
 
“BPM Pro 2 is designed to help remote patient monitoring programs scale effectively. It simplifies patient onboarding and education, enhances care teams’ confidence in measurement reliability, and automates routine tasks like symptom collection—all while providing an exceptional user experience that motivates patient engagement,” said Antoine Robiliard, VP of Withings Health Solutions. “While the surge in digital health in recent years has improved patient outcomes, it has often placed a strain on care teams. With BPM Pro 2, our goal is to restore their valuable time and empower them to focus on delivering high-quality care by streamlining workflows and reducing administrative burden.”
 
The Patient Insights feature streamlines clinical workflows by gathering critical information through the device such as symptoms and medication adherence which reduces clinical workload, freeing up care teams to dedicate time to patients with the highest need. This feature asks simple and customized questions through the device to capture additional information such as symptoms, medication adherence, sleep patterns, and screening questionnaires.
 
BPM Pro 2 can be configured to automatically cue the patients to retake their blood pressure if it hits a certain predetermined threshold. After years of care team input, the retake feature was designed to clarify abnormally high readings, which are often related to incorrect measurement techniques.
 
The device includes an easy-to-follow module that guides patients through best practices for taking blood pressure readings. On-screen visual instruction helps users understand proper measurement techniques, leading to more accurate home readings and an improved overall user experience.
 
Readings and all other displayed information are presented in bold text, ensuring ease of visibility. The screen incorporates a color-coded feedback system, where results are highlighted in distinct colors to facilitate quick and effortless interpretation.
 
Data is instantly synced via cellular connectivity allowing healthcare partners to access patient-generated data via their clinical platform or Withings RPM, its proprietary patient monitoring platform. For patients in cellular dead zones, BPM Pro 2 offers WiFi and Bluetooth fallback options, ensuring seamless connectivity and access to remote care for all.
 
BPM Pro 2 is planned to be available from November 2024, following FDA Clearance.

link

Leave a Reply

Your email address will not be published. Required fields are marked *